指南与共识白血病造血干细胞移植与细胞治疗

Menin抑制剂在儿童急性白血病中的应用:与成人白血病及国际社会合作加速进展的综合综述与建议

Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.
指南 / 共识 · Leukemia · 2024-08-23

本文综述了Menin抑制剂在KMT2A重排、NPM1突变等依赖Menin的白血病中的临床前与临床证据,提出将儿童人群纳入成人试验的未来国际临床试验设计建议,以加速儿童急性白血病患者获得该疗法的进程。

要点

  • Menin抑制剂对KMT2A重排和NPM1突变急性白血病显示显著临床疗效。
  • HOX与MEIS1异常表达导致分化阻滞,Menin抑制剂可解除该阻滞。
  • 建议未来开展国际、包容、高效的临床试验,将儿童纳入成人试验。

核心结论

  • Menin抑制剂对KMT2A重排和NPM1突变急性白血病具有显著临床疗效,有望满足多种儿童白血病亚型未满足的需求。
  • 作者建议未来开展国际、包容、高效的临床试验设计,将儿童人群纳入成人试验,以确保所有依赖Menin的白血病儿童和青少年广泛获得该疗法。

研究设计与样本

  • 本综述由儿童与成人血液科/肿瘤科医生及干细胞移植医生合作完成,整合临床前证据与正在进行的全球临床试验见解。

主要发现

  • HOX家族基因是生理性造血的必要守门员,其表达受KMT2A与Menin相互作用调控。
  • KMT2A重排、NUP98重排或NPM1突变白血病中HOX和MEIS1家族基因异常表达导致分化阻滞和白血病发生。
  • Menin抑制剂阻断KMT2A与Menin相互作用,下调MEIS1等转录因子异常表达,从而解除分化阻滞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and leukemia development. HOX family genes are essential gatekeepers of physiologic hematopoiesis, and their expression is regulated by the interaction between KMT2A and menin. Menin inhibitors block this interaction, downregulate the abnormal expression of MEIS1 and other transcription factors and thereby release the differentiation block. Menin inhibitors show significant clinical efficacy against KMT2A-rearranged and NPM1-mutated acute leukemias, with promising potential to address unmet needs in various pediatric leukemia subtypes. In this collaborative initiative, pediatric and adult hematologists/oncologists, and stem cell transplant physicians have united their expertise to explore the potential of menin inhibitors in pediatric leukemia treatment internationally. Our efforts aim to provide a comprehensive clinical overview of menin inhibitors, integrating preclinical evidence and insights from ongoing global clinical trials. Additionally, we propose future international, inclusive, and efficient clinical trial designs, integrating pediatric populations in adult trials, to ensure broad access to this promising therapy for all children and adolescents with menin-dependent leukemias.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Cuglievan B, Kantarjian H, Rubnitz JE, et al. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024. PMID: 39179671. doi:10.1038/s41375-024-02368-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。